Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07076641

Efficacy and Safety of Intravenous Lidocaine Versus Placebo in Patients Receiving Morphine-rachi Analgesia

The purpose of this study is to evaluate the superiority of IV lidocaine combined with morphine spinal anesthesia versus placebo combined with morphine spinal anesthesia, in reducing postoperative morphine consumption at 48 hours, in patients undergoing major digestive or abdominal surgery by laparotomy.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hôpital Privé Jean Mermoz

Lyon, 69008, France

Location contact

Florent SIGWALT, MD

CONTACT

[email protected]

About this study

This is a prospective, interventional, comparative, randomized, 2-group parallel, placebo-controlled, double-blind, single-center trial designed to evaluate the value of intravenous lidocaine combined with morphine rachi anesthesia in major laparotomy digestive or abdominal surgery.

The study corresponds to a clinical trial of a medicinal product in compliance with Regulation (EU) n°536/2014.

The study population is composed of adult patients receiving morphine spinal anesthesia for major laparotomy surgery and who have signed an informed consent form.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years;
  • Major digestive or abdominal surgery (pancreatic, hepatic, colorectal, gynecological, esophageal, gastric, duodenal, small intestine...);
  • Scheduled surgery;
  • Laparotomy;
  • Patient in agreement with morphine rachi anesthesia;
  • Social security affiliation;
  • Signed informed consent.

Exclusion criteria

  • Emergency surgery;
  • Contraindication to non-steroidal anti-inflammatory drugs: history of gastro duodenal ulcer, renal failure from stage 3 A or higher;
  • History of bradycardia and/or known conduction disorder (atrioventricular block) / Pacemaker ;
  • Unstable coronary ;
  • Myocardial infarction <6 months;
  • Severe cardiocirculatory insufficiency;
  • Severe hepatic insufficiency;
  • Allergy to morphine ;
  • Allergy to lidocaine;
  • Rhythm disorders at risk of sudden death (e.g. Brugada syndrome);
  • Flecaine as usual treatment;
  • Chronic pain with level II or III analgesics;
  • Gabapentinoids: pregabalin (Lyrica), gabapentin;
  • Drug addiction and substitute drugs;
  • Epileptic disorders ;
  • Myasthenia gravis;
  • Creatinine clearance below 10 mL/min;
  • Hypokalemia, hypoxia or acid-base disorders;
  • Patient participating in another clinical trial, or in a period of exclusion from another clinical trial;
  • Inability to understand study information (due to linguistic, psychological, cognitive or literacy problems);
  • Women who are or may become pregnant* (of childbearing age, without effective contraception) or who are breast-feeding;
  • Patient deprived of liberty, under guardianship or unable to give consent.

Treatment and study plan

rachi morphine anesthesia

Procedure

Morphine spinal anesthesia is administered before general anesthesia, just after the patient has been admitted to the operating room.

Laparotomy

Procedure

major digestive or abdominal surgery by laparotomy

Lidocaine IV

Drug

KABI 20 mg/mL solution for injection (ready-to-use ampoule, no dilution). Each ml of solution contains 20 mg lidocaine hydrochloride (monohydrate form), corresponding to 16.22 mg lidocaine.

Placebo

Drug

Sodium chloride (NaCl) FRESENIUS 0.9% solution for infusion. Each ml contains 9 mg sodium chloride.

Morphine

Drug

The auxiliary drug on which both experimental strategies are based is MORPHINE: Morphine hydrochloride AGUETTANT 0.1 mg/mL Solution for injection (ready-to-use ampoule) for rachi anesthesia.

Primary outcomes

  1. Total morphine consumption

    Time frame: 2 days

    Total consumption of morphine received postoperatively from the post-interventional monitoring room to 48 hours (in mg) by intravenous and patient-controlled analgesia, and oral dose converted to IV morphine equivalent where applicable.

Study contacts

Contact information is provided by the study sponsor or research team.

Florent SIGWALT, MD

CONTACT

[email protected]

688620169 ext. +33

Sponsors and collaborators

Lead sponsor

GCS Ramsay Santé pour l'Enseignement et la Recherche

Other

Collaborators

  • Euraxi Pharma

Registry information

Official study title

Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Intravenous Lidocaine Versus Placebo in Patients Receiving Analgesic Morphine Rachi Anesthesia for Major Digestive or Abdominal Surgery by Laparotomy.

Acronym: LIDORACHI

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 22, 2025
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.